May 2021: A panel discussion about the TELLOMAK clinical trial evaluating lacutamab in patients with advanced T-cell lymphomas, including Sézary syndrome and mycosis fungoides. Dr. Youn Kim and Dr. Joyson Karakunnel join Susan Thornton to discuss the clinical perspective of the study, where the study is today, preliminary data to share from the trial and more.

Panelists: 
Joyson Karakunnel, MD, MSc, FACP, Innate Pharma 
Youn Kim, MD, Stanford Health Care
Susan Thornton, CEO, Cutaneous Lymphoma Foundation

December 2020: Elorac is currently engaged in a clinical trial for topical naloxone, which targets itch in mycosis fungoides and Sezary Syndrome. Members of the Elorac team joined Susan Thornton for a discussion about this promising treatment for managing itch.

Panelists:
Heidi Fezatte, Director, Clinical Compliance, Elorac, Inc.
Scott Phillips, MD, Senior Vice President, Scientific Affairs, Elorac, Inc.
Susan Thornton, CEO, Cutaneous Lymphoma Foundation

June 2020: The FLASH (Fluorescent Light Activated Synthetic Hypericin) Study, a phase 3 trial by Soligenix, is a potential new treatment for early stage cutaneous lymphoma using visible fluorescent light. Susan Thornton, CEO, was joined by Drs. Ellen Kim, Chris Pullion and Richard Straube to discuss this exciting technology.

Panelists:
Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine
Richard Straub, MD, Chief Medical Officer, Soligenix, Inc.
Chris Pullion, DO, Medical Director, Soligenix Inc.

April 2020 - Helsinn Therapeutics (U.S.), Inc., the US subsidiary of the Swiss pharmaceutical group focused on building quality cancer care products, today announces a change to the financial assistance program for VALCHLOR® (mechlorethamine) gel 0.016% to ensure that commercially insured patients have access to treatment during the COVID-19 crisis.

Positive results were announced earlier this year for the FLASH Study, a phase 3 clinical trial in CTCL, by Soligenix. SGX301 is a novel first-in-class photodynamic therapy utilizing safe visible light for activation.

December 2019 - The American Society of Hematology (ASH) announced the 39 recipients of its 2020 Scholar Awards. One of ASH’s most prestigious research award programs, the ASH Scholar Awards financially support fellows to junior faculty dedicated to careers in hematology research as they transition from training programs to careers as independent investigators. Awardees included cutaneous lymphoma researcher, Anjali Mishra, PhD. 

Two clinical assets of Trillium Therapeutics Inc., TTI-621 and TTI-622, are designed to activate the patient’s innate and adaptive immune response. TTI-621 is an investigational agent being developed by Trillium for the treatment of cutaneous T-cell lymphoma and other cancer types.

The FDA has approved mogamulizumab-kpkc (Poteligeo) for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least 1 prior systemic therapy.

Susan Thornton, CEO, interviewed Adaptive Biotechnologies, creators of an innovative diagnostic tool that can be used in cutaneous lymphoma.

Dr. Ellen Kim shares information about the role of clinical trials and specifically the FLASH [Fluorescent Light Activated Synthetic Hypericin] Study.

Chronic rash in a sun-protected area that doesn’t respond to topical treatment likely needs to be evaluated for mycosis fungoides, the most common variant of cutaneous T-cell lymphoma. Now, a new VA study reports that a protein expression can help make the diagnosis.